|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.52 USD | -2.43% |
|
-1.96% | +78.09% |
| 05/03 | Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating | MT |
| 05/03 | US stocks close up on Iran diplomacy hopes; tech leads rebound | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 51.93 | 23.3 | -11.97 | -15.14 | -14.51 | |||||
Return on Total Capital | 93.06 | 33.28 | -14.96 | -18.44 | -17.79 | |||||
Return On Equity % | 146.08 | 50.27 | -28.59 | -28.77 | -28.87 | |||||
Return on Common Equity | 146.08 | 50.27 | -28.59 | -28.77 | -28.87 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 75.05 | 54.78 | -39.28 | -85.63 | -105.76 | |||||
SG&A Margin | 3.07 | 5.88 | 22.62 | 36.28 | 52.37 | |||||
EBITDA Margin % | 73.24 | 50.71 | -52.83 | -116.07 | -147.07 | |||||
EBITA Margin % | 71.98 | 48.9 | -61.9 | -121.91 | -158.13 | |||||
EBIT Margin % | 71.98 | 48.9 | -61.9 | -121.91 | -158.13 | |||||
Income From Continuing Operations Margin % | 66.06 | 43.41 | -68.84 | -110.04 | -145.16 | |||||
Net Income Margin % | 66.06 | 43.41 | -68.84 | -110.04 | -145.16 | |||||
Net Avail. For Common Margin % | 66.06 | 43.41 | -68.84 | -110.04 | -145.16 | |||||
Normalized Net Income Margin | 44.95 | 31.13 | -35.32 | -68.58 | -88.83 | |||||
Levered Free Cash Flow Margin | 50.31 | 19.04 | -34.8 | -95.41 | -68.24 | |||||
Unlevered Free Cash Flow Margin | 50.37 | 19.14 | -34.45 | -94.95 | -67.91 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.15 | 0.76 | 0.31 | 0.2 | 0.15 | |||||
Fixed Assets Turnover | 20.87 | 10.94 | 2.86 | 1.15 | 0.67 | |||||
Receivables Turnover (Average Receivables) | 8.09 | 8.45 | 5.86 | 4.97 | 6.71 | |||||
Inventory Turnover (Average Inventory) | 6.19 | 6.02 | 13.27 | 37.66 | 29.63 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.76 | 2.73 | 3.42 | 3.67 | 3.29 | |||||
Quick Ratio | 1.54 | 2.34 | 3.21 | 3.45 | 3.06 | |||||
Operating Cash Flow to Current Liabilities | 1.49 | 1.01 | -1.03 | -1.36 | -0.94 | |||||
Days Sales Outstanding (Average Receivables) | 45.11 | 43.2 | 62.29 | 73.58 | 54.41 | |||||
Days Outstanding Inventory (Average Inventory) | 58.93 | 60.67 | 27.51 | 9.72 | 12.32 | |||||
Average Days Payable Outstanding | 9.73 | 17.67 | 21.27 | 28.58 | 32.65 | |||||
Cash Conversion Cycle (Average Days) | 94.32 | 86.21 | 68.54 | 54.71 | 34.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 6.48 | 6.28 | 8.97 | 6.85 | 15.09 | |||||
Total Debt / Total Capital | 6.08 | 5.9 | 8.23 | 6.41 | 13.11 | |||||
LT Debt/Equity | 4.98 | 5.25 | 8.79 | 6.51 | 14.6 | |||||
Long-Term Debt / Total Capital | 4.68 | 4.94 | 8.07 | 6.1 | 12.69 | |||||
Total Liabilities / Total Assets | 42.66 | 26.05 | 24.81 | 22.92 | 29.89 | |||||
EBIT / Interest Expense | 738.67 | 324.83 | -111.55 | -164.38 | -307.4 | |||||
EBITDA / Interest Expense | 761.17 | 344.17 | -89.87 | -149.92 | -274.8 | |||||
(EBITDA - Capex) / Interest Expense | 745.39 | 330.38 | -108.47 | -193.71 | -294 | |||||
Total Debt / EBITDA | 0.07 | 0.12 | -0.36 | -0.21 | -0.47 | |||||
Net Debt / EBITDA | -1.22 | -1.71 | 3.53 | 2.44 | 2.49 | |||||
Total Debt / (EBITDA - Capex) | 0.07 | 0.13 | -0.3 | -0.16 | -0.44 | |||||
Net Debt / (EBITDA - Capex) | -1.24 | -1.78 | 2.92 | 1.89 | 2.32 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 2.2T | 4.29 | -64.45 | -52.75 | -39.93 | |||||
Gross Profit, 1 Yr. Growth % | -2.51T | -23.88 | -125.49 | 3.01 | -25.8 | |||||
EBITDA, 1 Yr. Growth % | -1.95T | -27.79 | -137.04 | 3.81 | -23.88 | |||||
EBITA, 1 Yr. Growth % | -1.84T | -29.15 | -145 | -6.94 | -22.08 | |||||
EBIT, 1 Yr. Growth % | -1.84T | -29.15 | -145 | -6.94 | -22.08 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -1.73T | -31.47 | -156.37 | -24.46 | -20.75 | |||||
Net Income, 1 Yr. Growth % | -1.73T | -31.47 | -156.37 | -24.46 | -20.75 | |||||
Normalized Net Income, 1 Yr. Growth % | -1.88T | -27.77 | -140.33 | -8.24 | -22.19 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -1.54T | -28.88 | -161.33 | -24.8 | -21.77 | |||||
Accounts Receivable, 1 Yr. Growth % | 128.25 | -56.38 | -35.6 | -59.87 | -48.6 | |||||
Inventory, 1 Yr. Growth % | 2.97T | -32.41 | -76.88 | -42.08 | 30.77 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 257.36 | 54.66 | 24.26 | 11.17 | -3.45 | |||||
Total Assets, 1 Yr. Growth % | 236.23 | 4.82 | -28.74 | -23.25 | -12.76 | |||||
Tangible Book Value, 1 Yr. Growth % | 452.32 | 35.19 | -28.06 | -21.43 | -20.87 | |||||
Common Equity, 1 Yr. Growth % | 452.32 | 35.19 | -27.55 | -21.32 | -20.65 | |||||
Cash From Operations, 1 Yr. Growth % | 571.93 | -63.43 | -162.6 | -3.66 | -37.65 | |||||
Capital Expenditures, 1 Yr. Growth % | 317.65 | 40.84 | 76.75 | 48.66 | -81.73 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 324.3 | -60.53 | -164.95 | 29.56 | -57.04 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 323.6 | -60.38 | -163.98 | 30.23 | -57.03 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.65T | 389.78 | -39.11 | -59.01 | -46.72 | |||||
Gross Profit, 2 Yr. CAGR % | 463.88 | 328.38 | -55.95 | -48.76 | -12.58 | |||||
EBITDA, 2 Yr. CAGR % | 412.52 | 265.3 | -48.28 | -37.99 | -11.11 | |||||
EBITA, 2 Yr. CAGR % | 393.47 | 251.37 | -43.54 | -35.29 | -14.84 | |||||
EBIT, 2 Yr. CAGR % | 393.47 | 251.37 | -43.54 | -35.29 | -14.84 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 387.23 | 234.58 | -37.84 | -34.74 | -22.63 | |||||
Net Income, 2 Yr. CAGR % | 387.23 | 234.58 | -37.84 | -34.74 | -22.63 | |||||
Normalized Net Income, 2 Yr. CAGR % | 407.88 | 259.12 | -46.03 | -39.1 | -16.28 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 326.82 | 220.34 | -33.95 | -32.09 | -23.33 | |||||
Accounts Receivable, 2 Yr. CAGR % | 2.33T | -0.22 | -47 | -49.16 | -54.58 | |||||
Inventory, 2 Yr. CAGR % | - | 398.51 | -60.47 | -68.35 | -12.97 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 119.17 | 135.1 | 38.63 | 17.54 | 3.6 | |||||
Total Assets, 2 Yr. CAGR % | 293.96 | 87.73 | -13.57 | -26.05 | -18.17 | |||||
Tangible Book Value, 2 Yr. CAGR % | 246.99 | 173.26 | -1.38 | -24.82 | -21.15 | |||||
Common Equity, 2 Yr. CAGR % | 246.99 | 173.26 | -1.03 | -24.5 | -20.98 | |||||
Cash From Operations, 2 Yr. CAGR % | 444.73 | 56.76 | -52.15 | -22.34 | -22.49 | |||||
Capital Expenditures, 2 Yr. CAGR % | 197.91 | 142.54 | 57.78 | 62.1 | -47.89 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 431.67 | 29.42 | -49.36 | -8.26 | -25.02 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 431.99 | 29.55 | -49.64 | -8.7 | -25.2 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 415.2 | 584.74 | 104.31 | -44.04 | -53.44 | |||||
Gross Profit, 3 Yr. CAGR % | 251.57 | 189.26 | 67.25 | -41.53 | -42.03 | |||||
EBITDA, 3 Yr. CAGR % | 226.58 | 166.69 | 70.34 | -34.76 | -33.6 | |||||
EBITA, 3 Yr. CAGR % | 218.05 | 158.4 | 77.11 | -33.3 | -31.15 | |||||
EBIT, 3 Yr. CAGR % | 218.05 | 158.4 | 77.11 | -33.3 | -31.15 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 216.54 | 153.39 | 84.79 | -33.67 | -30.38 | |||||
Net Income, 3 Yr. CAGR % | 216.54 | 153.39 | 84.79 | -33.67 | -30.38 | |||||
Normalized Net Income, 3 Yr. CAGR % | 224 | 165.1 | 73.27 | -35.58 | -33.92 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 78.74 | 134.87 | 84.63 | -31.03 | -28.83 | |||||
Accounts Receivable, 3 Yr. CAGR % | 531.87 | 536.58 | -13.77 | -51.69 | -48.97 | |||||
Inventory, 3 Yr. CAGR % | - | - | 79.1 | -59.24 | -49.21 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 86.86 | 95.13 | 90.09 | 28.8 | 10.08 | |||||
Total Assets, 3 Yr. CAGR % | 132.53 | 153.39 | 35.93 | -16.93 | -21.86 | |||||
Tangible Book Value, 3 Yr. CAGR % | 109.87 | 153.43 | 75.14 | -8.58 | -23.52 | |||||
Common Equity, 3 Yr. CAGR % | 109.87 | 153.43 | 75.54 | -8.32 | -23.24 | |||||
Cash From Operations, 3 Yr. CAGR % | 245.28 | 121.4 | 15.44 | -39.58 | -27.82 | |||||
Capital Expenditures, 3 Yr. CAGR % | 38.99 | 132.08 | 118.26 | 54.68 | -21.7 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 233.02 | 123.46 | 2.85 | -30.74 | -28.76 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 234.01 | 123.83 | 2.41 | -30.88 | -28.99 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 179.44 | 147.88 | 119.28 | 122.01 | 19.34 | |||||
Gross Profit, 5 Yr. CAGR % | 142.2 | 120.02 | 53.18 | 44.75 | 29.02 | |||||
EBITDA, 5 Yr. CAGR % | 130.34 | 108.35 | 56.26 | 48.79 | 31.32 | |||||
EBITA, 5 Yr. CAGR % | 126.35 | 103.58 | 59.3 | 48.52 | 32.14 | |||||
EBIT, 5 Yr. CAGR % | 126.35 | 103.58 | 59.3 | 48.52 | 32.14 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 124.03 | 100.84 | 65.06 | 47.27 | 30.45 | |||||
Net Income, 5 Yr. CAGR % | 124.03 | 100.84 | 65.06 | 47.27 | 30.45 | |||||
Normalized Net Income, 5 Yr. CAGR % | 128.6 | 106.6 | 58.2 | 47.13 | 30.01 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 49.47 | 36.9 | 20.02 | 42.98 | 29.91 | |||||
Accounts Receivable, 5 Yr. CAGR % | 197.94 | 152.79 | 134.48 | 131.63 | -33.27 | |||||
Inventory, 5 Yr. CAGR % | - | - | - | - | 26.62 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 76.3 | 72.75 | 65.83 | 59.32 | 49.11 | |||||
Total Assets, 5 Yr. CAGR % | 77.07 | 88.57 | 56.51 | 54.83 | 10.95 | |||||
Tangible Book Value, 5 Yr. CAGR % | 111.43 | 103.25 | 55.15 | 55.87 | 27.27 | |||||
Common Equity, 5 Yr. CAGR % | 111.43 | 103.25 | 55.37 | 56.13 | 27.56 | |||||
Cash From Operations, 5 Yr. CAGR % | 189.71 | 71.94 | 56.62 | 45.61 | -1.57 | |||||
Capital Expenditures, 5 Yr. CAGR % | 53.67 | 46.94 | 46.22 | 101.04 | 23.07 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 93.35 | 56.78 | 56.51 | -9.54 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 93.56 | 56.71 | 56.36 | -9.68 |
- Stock Market
- Equities
- MRNA Stock
- Financials Moderna, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















